Effects of Tirofiban Combined with Ticagrelor in Patients with Postoperative Coronary Heart Disease
Objective To investigate the efficacy of ticagrelor combined with tirofiban in patients with coronary heart disease after percutaneous coronary intervention(PCI),and to analyze the effects on cardiac function and inflammatory factors.Methods A total of 135 patients with coronary heart disease who received PCI in the hospital from October 2020 to October 2022 were selected as the study objects and randomly divided into control group A(45 cases),control group B(45 cases)and combination group(45 cases).After surgery,control group A was treated with ticagrelor,control group B was treated with tirofiban,and combination group was treated with tirofiban and ticagrelor,all of them were treated for 2 months.The clinical efficacy,cardiac function[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),fractional shortening(FS)],myocardial injury markers[creatine kinase isoenzyme(CK-MB),cardiac troponin Ⅰ(cTn Ⅰ),cardiac troponin T(cTnT)]and inflammatory factor[highly sensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)]and peripheral blood PI3 K/AKT signaling pathway related proteins[phosphoryl phosphatidylinositol-3-kinase(p-PI3K),phosphorylated Akt(p-AKT)]of the 3 groups were compared before and after treatment.After 6 months of follow-up,the incidence of major adverse cardiovascular events(MACE)during treatment was measured.Results The total effective rate of combined group was higher than that of control group A and control group B,and the incidence of MACE was lower than that of control group A and control group B(P＜0.05).After treatment,LVEF and FS in combination group were higher than those in control group A and control group B,and LVEDD was lower than those in control group A and control group B(P＜0.05).After treatment,the serum levels of CK-MB,cTn Ⅰ,cTnT,hs-CRP,TNF-α and IL-6 in combination group were lower than those in control group A and control group B,and the levels of P-PI3 K and P-AKT protein in peripheral blood of combined group were higher than those of control group A and control group B(P＜0.05).There was no stastitical difference between control group A and control group B(P＞0.05).Conclusion The combined treatment of tirofiban and tiagrelor in patients with coronary heart disease after PCI has significant effects,which can improve cardiac function,alleviate myocardial injury,inhibit inflammatory response,and reduce the occurrence of MACE,which may be related to the regulation of PI3K/AKT signaling pathway.
万方数据
维普
